UCB’s Bimzelx Impresses In Psoriatic Arthritis Amid US Psoriasis Approval Delay

 
• By Ayisha Sharma

UCB’s Bimzelx has forged ahead with success in a late-stage psoriatic arthritis trial while it still awaits US approval for psoriasis, a hotly anticipated blockbuster indication.  

UCB Celebrates Win In Psoriatic Arthritis Even As Regulatory Wait Is Prolonged • Source: Alamy

More from Clinical Trials

More from R&D